K. Bell

发表

Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.

J. Boyd, S. Rubin, T. Randall, 1998, Gynecologic oncology.

Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer

M. Levine, B. Sadikovic, K. Bell, 2014, Breast Cancer Research and Treatment.

Genetic Counselling Referral Rates and Uptake of BRCA1 and BRCA2 Testing among Women Diagnosed with Serous Ovarian Cancer in a Tertiary Care Cancer Centre

G. Pond, L. Elit, K. Bell, 2013 .

Development of a comprehensive approach to adult hereditary cancer testing in Ontario

H. Feilotter, A. Pollett, A. Eisen, 2022, Journal of Medical Genetics.

Clinical and molecular delineation of the 17q21.31 microdeletion syndrome

L. Vissers, B. D. de Vries, E. Eichler, 2008, Journal of Medical Genetics.

Early onset of renal cancer in a family with Birt–Hogg–Dubé syndrome

D. de Jong, I. Kluijt, S. Horenblas, 2009, Clinical genetics.

ATM whole gene deletion in an Italian family with hereditary pancreatic cancer: Challenges to cancer risk prediction associated with an 11q22.3 microdeletion.

D. Grafodatskaya, R. White, B. Eng, 2019, Cancer genetics.

Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry

G. Pond, S. Gallinger, M. Aronson, 2017, Journal of Medical Genetics.

Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer.

K. Bell, S. Hsu, A. G. Perna, 2001, Journal of the American Academy of Dermatology.

Isamed Journals

G. Pond, L. Elit, H. Hirte, 2017 .

P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial): Topic: EGFR Clinical

A. Hackshaw, J. Spicer, Y. Ngai, 2017 .